ADZYNMA (ADAMTS13, recombinant-krhn) is now in stock with Orsini and ready for distribution. Orsini is the exclusive specialty pharmacy partner for...
ELK GROVE VILLAGE, Ill., Nov. 20, 2023 /PRNewswire/ -- Orsini Specialty Pharmacy has been selected by Takeda Pharmaceuticals as the exclusive specialty...
Orsini Specialty Pharmacy has been selected by Amicus Therapeutics to dispense Pombiliti™ (cipaglucosidase alfa-atga) and Opfolda™ (miglustat), a...
ELK GROVE VILLAGE, IL – August 2023 – Orsini Specialty Pharmacy ("Orsini"), a leading independent specialty pharmacy focused on rare diseases and gene...
ELK GROVE VILLAGE, IL – Aug. 23, 2023 – Orsini Specialty Pharmacy ("Orsini"), a leading independent specialty pharmacy focused on rare diseases and...
Orsini Specialty Pharmacy, a leading independent specialty pharmacy focused on rare diseases and gene therapies, announced that BioMarin Pharmaceutical...
The complexities of managing the care of a rare disease patient are tremendous. Several models of care are efficient when optimizing patient care...
Orsini Specialty Pharmacy, a leading independent specialty pharmacy focused on rare diseases and gene therapies, has been selected by Sarepta...
Orsini Specialty Pharmacy, a leader in rare diseases and gene therapies, announced that Aimmune Therapeutics, a Nestle Health Science Company, has...
Recurrent Pericarditis (RP) is a painful auto-inflammatory cardiovascular disease that occurs when patients with acute pericarditis experience one or...
Orsini is a leading independent national specialty pharmacy accredited by ACHC, JCAHO, URAC, and VIPPS. The services we provide allow patients, physicians, payors, and manufacturers to improve care, simplify processes, and achieve better outcomes.
Now In Stock: ADZYNMA (ADAMTS13, recombinant-krhn), for patients with cTTP
Orsini Specialty Pharmacy Selected as Distribution Partner for Adzynma (ADAMTS13, recombinant-krhn), a Newly Approved Treatment for an Ultra-Rare Blood Clotting Disorder
Orsini Specialty Pharmacy Partners with Amicus Therapeutics to Dispense New Therapy for the Treatment of Late-Onset Pompe Disease
Orsini Specialty Pharmacy Names Darin DeCarlo Chief Growth Officer
Orsini Specialty Pharmacy Selected to be the Exclusive Specialty Pharmacy Partner for VEOPOZ™ (pozelimab-bbfg), the First and Only Treatment for CHAPLE Disease
.jpg?width=1754&height=637&name=SP_Logo_Color_RGB%202020update%20(1).jpg "Orsini Specialty Pharmacy Logo"){kind=logo}
![[Whitepaper] Payor Considerations When Choosing a Specialty Pharmacy](https://no-cache.hubspot.com/cta/default/7642930/d6329582-47a1-404d-b2a8-63c2637a9807.png)